Cardiovascular disease (CVD) is responsible for significant morbidity and premature mortality in Australia. Ischaemic heart disease was the leading cause of death in 2020 and cerebrovascular disease was the third most common cause of death.
As the first major update to Australian CVD risk assessment guidelines in over a decade, the 2023 Australian Guideline for assessing and managing cardiovascular disease risk and associated Aus CVD Risk Calculator reflect the latest evidence on assessing, communicating, and managing CVD risk. Developed using Australian-specific data and the latest evidence, it supersedes the 2012 Guidelines for the management of absolute cardiovascular disease risk.
New cardiovascular disease (CVD) Risk Guidelines were commissioned by the Australian Government Department of Health and Aged Care, and developed by the Heart Foundation on behalf of the Australian Chronic Disease Prevention Alliance (ACDPA) (Diabetes Australia, Kidney Health Australia and Stroke Foundation). The guideline has been endorsed by the Royal Australian College of General Practitioners (RACGP).
The new guideline has been developed according to the processes and standards outlined in the 2016 Australian National Health and Medical Research Council’s (NHMRC) Guidelines for Guidelines.
The guideline was developed under the direction and governance of nine expert advisory groups with multidisciplinary clinical and consumer input (see Appendix 1). Expertise was sourced across the disciplines of cardiology, general practice, nephrology, neurology, endocrinology, stroke care, epidemiology, Indigenous health, nutrition, behavioural science, nursing and pharmacy. Special attention was given to First Nations people’s health, and the Indigenous Health Expert Subgroup advised on every aspect of the guideline development.
The project aim was to develop an updated CVD Risk clinical guideline and corresponding CVD risk prediction algorithm enabling best practice assessment and management of CVD risk, overseen by the Guideline Advisory Group which consists of representatives from the ACDPA.
An individual’s risk of developing CVD depends on the combined effect of multiple risk factors. Risk assessment, therefore, remains fundamental to the early detection and prevention of CVD. The guideline encourages early modification of CVD risk factors, helps target medicines to those who will benefit most, and informs clinical decision-making.
The guideline and calculator help healthcare professionals assess, communicate and manage a person’s risk of developing cardiovascular disease. Australian Health Journal spoke with cardiologist and Heart Foundation Chief Medical Advisor, Professor Garry Jennings AO on how HCPs in primary health care can use the resources, guideline and risk calculator in clinical practice.
You Might also like
-
Co-design, adoption and interoperability
In October CEBIT AUSTRALIA held it’s yearly technology related conference. Australian Health Journal’s reporter Anne Dao spoke with health technology thought leaders on what needs to be consider in Co-Design, Adoption and Interoperability of technology aided healthcare delivery
-
Hair’s-breadth endoscopes to detect plaque
This coming World Heart Day (29th September 2021), Australian Health Journal’s People in Health Care series, releases a segment on Dr Jiawen Li.
Dr Jiawen Li is an inventor and highly adaptable engineer leading the intravascular imaging program at the Institute of Photonics and Advanced Sensing (IPAS). She has developing an imaging device can be inserted into blood vessels to provide high quality 3D images to help scientists better understand the causes of heart attack and heart disease progression, and could lead to improved treatment and prevention.
-
AHJ S1E4: TAVI 10 Year Anniversary
2018 marks the 10 year anniversary of the TAVI device, short for the Transcatheter Aortic Valve Implantation. The TAVI system enables the replacement of a diseased aortic valve without open-heart surgery or surgical removal of the native valve.
This minimally invasive surgical option reduces operating time and allows for a shortened recovery period for patients.
AHJ met with the cardiologist teams in Melbourne’s Epworth and Alfred Hospital who have involved in implanting the device over the past 10 years.
Interviews:
- Associate Professor Tony Walton, Epworth Hospital, Director of Catheter Laboratory and Deputy Director of Cardiology – Alfred Health
- Associate Professor Ron Dick, Director of Cardiac Sciences – Epworth Healthcare
- Professor Stephen Duffy, Alfred Health
Post Views:
543